Equip Health vs Danaher Corporation
Side-by-side comparison of AI visibility scores, market position, and capabilities
Virtual eating disorder treatment using family-based therapy, San Diego CA, raised $58M+. First at-home model for anorexia and bulimia treatment in the US.
About
Equip Health is a San Diego, California-based virtual care company founded in 2019 that specializes in treating eating disorders including anorexia, bulimia, binge eating disorder, and avoidant restrictive food intake disorder (ARFID). The company has raised over $58 million and has pioneered a virtual delivery model for family-based treatment (FBT), the gold-standard evidence-based therapy for adolescent eating disorders, making intensive evidence-based care accessible outside of residential treatment programs.\n\nEquip's care model assembles a five-person care team for each patient: a therapist, a dietitian, a physician, a family mentor, and a peer mentor — all coordinating through the platform. This team-based virtual approach mirrors the multidisciplinary structure of leading eating disorder treatment centers while eliminating the geographic and financial barriers that prevent most patients from accessing residential care. Sessions are conducted by video with the patient and their family, with meal support and between-session coaching embedded in the program.\n\nThe company distributes its services through insurance coverage, accepting major commercial plans and working to expand Medicaid coverage. Eating disorders carry the highest mortality rate of any psychiatric illness, yet treatment access is severely limited in the United States. Equip's virtual model has treated patients across all 50 states, demonstrating the feasibility of delivering intensive eating disorder care at home and positioning the company as a national provider in a historically fragmented specialty.
Washington DC life sciences instruments (NYSE: DHR) at $23.9B FY2024 revenue; Cytiva bioprocessing, Beckman Coulter diagnostics, biopharma destocking recovery, 2025 core revenue +3% guidance competing with Thermo Fisher.
About
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, manufacturing, and marketing analytical instruments, reagents, consumables, software, and services for life sciences research, clinical diagnostics, and environmental monitoring through approximately 65,000 employees worldwide. In fiscal year 2024, Danaher reported revenues of $23.9 billion (flat year-over-year) with non-GAAP core revenue declining 1% as the biopharma sector's inventory destocking cycle continued, with Q4 2024 revenue of $6.5 billion (+2.0% reported, +1.0% core) representing an inflection toward recovery, generating $6.7 billion in operating cash flow and $5.3 billion in free cash flow. Danaher guided 2025 core revenue growth of approximately 3% — marking the expected return to growth as biopharma customers who destocked pandemic-era bioprocessing supply surpluses return to normalized purchasing. CEO Rainer Blair leads Danaher's post-spinoff strategy: in September 2023, Danaher separated its Environmental & Applied Solutions segment as Veralto Corporation (NYSE: VLTO), creating two independent public companies — Danaher (pure-play life sciences and diagnostics) and Veralto (water quality and product identification). Danaher's current portfolio centers on bioprocessing (Cytiva's bioreactors, membranes, single-use manufacturing for drug production), clinical diagnostics (Beckman Coulter chemistry and hematology analyzers, Radiometer blood gas analyzers, Cepheid molecular diagnostics), and life sciences research instruments (SCIEX mass spectrometry, Leica Microsystems microscopy).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.